This is a list of guidelines for the safety of veterinary medicines as issued by the European Medicines Agency (EMA) and the International Veterinary Conference on Harmonization (VICH).

The page is structured and contains instructions from the field of toxicology, user safety, environmental safety, and guidance on residue safety assessment (lead times, MRLs). Please click here: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_c ontent 000384.jsp&mid=WC0b01ac058002dd37

In addition to the guidelines mentioned below, the EMA also publishes and updates a list of frequently asked questions and answers concerning MRL determination, please click here: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q and a detail 00003 9.jsp&mid=WC0b01ac058002d89b

Â

<u>List of scientific guidelines on the safety - part III.A :</u>

TOXICOLOGY

Name Number Effective from Note

VICH GL22 Safety studies for where with a hy 525 commodue of the commodulation of

USER SAFETY

Number Effective from Name Note

User safety for pharmaceut ENEALEN/AP/5AEd20031 Beod 11/cts/2010 Rev. 1

User safety of topically admiritished to the safety of the s

Draft guideline

Â

ENVIRONMENTAL RISK ASSESSMENT

Name Number Effective from Note

VICH GL6 Environmental in 00 AlvitPalysics 1/50 1/2019 (Fig. 8.5) followed a firm as a limit of the company of

Assessment of persistent, beidalacommente and breide lineaccumulate Assessment of persistent and breide lineaccumulate and Authorisation of veterinary no both control of veterinary no both

Determining the fate of veterilation of veteri Guideline

Higher tier testing to investigate with the control of the control Plant testing strategy for veterinary medicinal products

EMA/CVMP/ERA/689041/2001/50/2017

Guideline

Assessing the environmenta EMACOVM R/IE TRANTO 055/55/2016 Identification and productive in ingreound water

Poorly extractable and/or notal Addivide the Assubsize 14

Reflection paper

Risk-mitigation measures related/Covinte de milatorio de la company de l

ERA - QaA document impletive that to the control of the control of

Antimicrobial resistance in the environment

EMEA/CVMP/ERA/6321-09/2014

Reflection paper

ERA-QaA document in £1/10/16/2016/26/2016/2016/2016 on the assessment of pe@ 4. bioaccumulative and to

Interpretation of Article 1881/7A/611-VR48 LEARIA/6/2204-2/02/03/6 Reflection paper

Interpretation of Article 72/MARRACMIRATED A A E24520-192621 Reflection paper

Criteria for determining to MANC ANTIPETS INSTALLANCE STEELS IN CONTROL OF Article 37

Environmental risk assessment of ectoparasiticidal veterinary medicinal products used in cats and dogs

EMA/CVMP/ERA/31905/2021

Draft Reflection paper

<u>List of scientific guidelines on the safety - part III.B :</u>

RESIDUES/WITHDRAWAL PERIODS

Number Effective from Note Name Approach towards harm Ein Earl 600 Vol Mill 200 Appear i Odl 51 997 Under revision Updated application software: withdrawal time calculation for tissues web page EMA Determination of withdra ENA Eparlo 2004 From 1898 08/09/2000 Under revision Updated application software: withdrawal time calculation for milk web page EMA

Injection-site residues EMEA/CVMP/542/2003 13/04/2005

Setting health based explater/ Children 160 Ms Setting health based explater in the malnufercter is in the malnufercter is in the malnufercter is in the malnufercter is in the malnufercter in the malnufercter in the malnufercter is in the malnufercter in the malnufercter in the malnufercter is in the malnufercter VICH GL46 studies to evenue. We will be a considered to the construction of veterinary drugs in food-producing the construction of VICH GL47 studies to everweater (CVAVIPEVAIGH)/sho330040/2930002 kinetics of veterinary drugs in food-producing VICH GL48 studies to evaluate checking to be leaded to the leader of the VICH GL49 studies to evenue. We will be with the wild be with the wild be will be will be with the wild be will be win the will be wil VICH GL56 studies to everward which which and the studies of the studies of the studies of the studies in food-producing the studies of the s VICH GL57 on studies to MANO and Phatel Material of its 200 /2004 200 to the studies to the stud

Introducing a review and ENDALATA INTROBER SERVING BEREAL 2018 A residues stoolies expot praince these into line with

Â

MAXIMUM RESIDUE LIMITS (MRL'S)

Effective from Name Number Note

Approach to establish a phachilate/lagiver/basacataledaily/0061/2004 (ADI)

Data to be provided in supple to EA2C to the State of the list of substances considered Risk-analysis approach for Edstill A&S VollMPM 1837/1000 rood of 10x00/11/122010 od rigin

VICH GL36 Studies to evaluate to evaluate to evaluate the content of the content Assessment of bioavailability Mo Elad Civid Messay Ness 5682 2200 09/2000 8 es of animal or Bierlier tilon campters of Consideration of adjuvants @ WMP & SEP valor / 290 Index Columbration (EEC) No Reservation (ACC) No Reservation (A New approach developed low the 16 with the Approaches on how to consider A 200 WHY 228005/2005 2005 22/of 1 1200 5 ation 2377/90 Concept paper

Definition of substances capablePoDpaarageCollegical action 04/2001eOcontext of CourrolsDirectPape2001/82

Establishment of maximum Establishment of maxi

AVAILABILITY (MINOR USES / MINOR SPECIES)

Name Number Effective from Note

Guideline on safety and restand to the content of MRLs for Salina (1000) and the content of MRLs for Salina (1000)

Position paper regarding availabilatyContine and maximum res

Â

MULTIDISCIPLINARY

Name Number Effective from Note Guideline on pharmaceutica (Co/M/DF/238004/005 ducts/2006 - Investigation of chiral active (s/356) (s/24/906) - 01/10/1993 -